drugset
drugset / Trial / NCT04828395

Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer

NCT04828395 ↗

Phase 2 Unknown 65 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedSingle-groupOpen-labelTreatment

Summary

Fluzoparib combined with Camrelizumab for maintenance treatment of locally advanced non-small cell lung cancer after concurrent radiotherapy and chemotherapy

Timeline

Start
2021-03-01
Primary completion
2023-03-01
Completion
2025-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Fluzoparib Small molecule 150 mg —
Background Carboplatin Small molecule 6 unknown —
Background Cisplatin Other / unclassified 50 mg/m2 Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Etoposide Small molecule 50 mg/m2 Intravenous
Background Paclitaxel Small molecule 100 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma